| Project/Area Number |
12470319
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Anesthesiology/Resuscitation studies
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
MARUYAMA Kazuo Mie University, Medicine, professor, 医学部, 教授 (20181828)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
AMANO Homare Mie University, Hospital, Assistant, 医学部・附属病院, 助手 (90231993)
MARUYAMA Junko Mie University, Medicine, lecturer, 医学部, 講師 (50263017)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥4,900,000 (Direct Cost: ¥4,900,000)
Fiscal Year 2001: ¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2000: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | Pulmonary hypertension / calcium / 一酸化窒素 |
|---|
| Research Abstract |
To determine if increased Ca sensitivity is observed in pulmonary hypertension, we measured pulmonary pressure in pulmonary hypertensive rats after administration of Rho-kinase inhibitor. As pulmonary hypertensive rats, two models were used : chronic hypoxic pulmonary hypertension and monocrotaline-induced pulmonaryhypertension. We used Y-27632 as Rho-kinase inhibitor which had been used to show increased Ca sensitivity in systemic hypertension. Y-27632 reduced pulmonary artery pressure in both model of pulmonary hypertension, while saline did not reduced pulmonary artery pressure. This results suggested that increased Ca sensitivity might be a part of pathogenesis of pulmonary hypertension. In addition, to determine if chronic administraction of Rho-kinase inhibitor might prevent the development of pulmonary hypertension and hypertensive pulmonary vascular changes, we gave Y-27632 to rats during 10days hypoxic exposure. Chronic administration of Y-27632 did not prevent the development of pulmonary hypertension and hypertensive pulmonary vascular changes. In terms of chronic effects of Rho-kinase inhibition on the development of pulmonary hypertension, we need to investigate another Rho-kinase inhibitor.
|
